Home>Topics>Stocks>Alexza Pharmaceuticals

Alexza Pharmaceuticals ALXA

  1. All
  2. Commentary
  3. Headlines
    1. Midday Gainers / Losers

      Headlines

      Fri, 8 Aug 2014

      LRAD +18% . PGEM +16% . WHX +16% . MELI +15% . SHOR +14% . Top 10 Losers: MBII -43% . IRG -32% . HGR -28% . VOLC -26% . RBCN -24% . POST -18% . ALXA -18% . EAC -18% . SEM -18% . RATE -17% . Post your comment!

    2. More on Alexza Pharma Q2 results

      Headlines

      Fri, 8 Aug 2014

      Alexza Pharmaceuticals ( ALXA -21.8% ) Q2 results : Revenues: $1.5M (-96.6%); Operating Expenses: $12.8M (+2.1%); Operating Loss

    3. Alexza Pharmaceuticals ( ALXA ) Q2 2014 Results - Earnings Call Webcast

      Headlines

      Thu, 7 Aug 2014

      The following audio is from a conference call that will begin on August 07, 2014 at 17:00 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »

    4. Alexza Pharma beats by $0.33, misses on revenue

      Headlines

      Thu, 7 Aug 2014

      Alexza Pharma (NASDAQ: ALXA ): Q2 EPS of -$0.34 beats by $0.33 . Revenue of $1.48M (-96.6% Y/Y) misses by $0.76M . Shares -2% . Press Release Post your comment!

    5. Alexza resubmits drug application early, shares soar

      Headlines

      Fri, 22 Jun 2012

      (Reuters) - Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.

    6. Setback for Valeant's Drug Candidate Adusuve Staccato

      Commentary

      Mon, 11 Oct 2010

      Valeant Pharmaceuticals VRX announced Monday that its partner Alexza Pharmaceuticals ALXA received a complete response letter on drug candidate adusuve staccato (formerly known as staccato loxapine). We will maintain

    7. Dropping Coverage of Alexza

      Commentary

      Mon, 7 Sep 2009

      We are no longer providing equity research on Alexza Pharmaceuticals ALXA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    8. Alexza to Acquire Longtime Partner

      Commentary

      Tue, 16 Jun 2009

      Alexza Pharmaceuticals ALXA announced that it has exercised its option to purchase longtime partner Symphony Allegro in a deal expected to close in the third

    9. Cash Still a Concern for Alexza

      Commentary

      Fri, 8 May 2009

      Despite Alexza Pharmaceuticals ' ALXA success at narrowing its net loss for the first quarter, we are keeping our fair value estimate in place because of our continuing

    10. Alexza under Review

      Commentary

      Fri, 30 Jan 2009

      We are putting Alexza Pharmaceuticals ALXA under review after the firm announced that it will reduce its workforce by 33% and halt certain early-stage drug-development

    « Prev12Next »
    Content Partners